{"title":"胸膜偏二胺的作用:它们有临床意义吗?","authors":"G. Sesti","doi":"10.30682/ildia2202b","DOIUrl":null,"url":null,"abstract":"Sixty years after its introduction in the therapeutic arsenal of type 2 diabetes, metformin remains the first-line treatment of type 2 diabetes according to national and international guidelines. Numerous obser¬vational studies have suggested that metformin may exert beneficial therapeutic effects on diabetes - and nondiabetes - related comorbidi¬ties, including cardiovascular, hepatic, neoplastic, and infectious dis¬eases. However, direct evidence of the pleiotropic effects of metformin from specific randomized controlled trials is still lacking.","PeriodicalId":119243,"journal":{"name":"Il Diabete","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effetti pleiotropici della metformina: hanno rilevanza clinica?\",\"authors\":\"G. Sesti\",\"doi\":\"10.30682/ildia2202b\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sixty years after its introduction in the therapeutic arsenal of type 2 diabetes, metformin remains the first-line treatment of type 2 diabetes according to national and international guidelines. Numerous obser¬vational studies have suggested that metformin may exert beneficial therapeutic effects on diabetes - and nondiabetes - related comorbidi¬ties, including cardiovascular, hepatic, neoplastic, and infectious dis¬eases. However, direct evidence of the pleiotropic effects of metformin from specific randomized controlled trials is still lacking.\",\"PeriodicalId\":119243,\"journal\":{\"name\":\"Il Diabete\",\"volume\":\"11 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Il Diabete\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30682/ildia2202b\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Il Diabete","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30682/ildia2202b","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effetti pleiotropici della metformina: hanno rilevanza clinica?
Sixty years after its introduction in the therapeutic arsenal of type 2 diabetes, metformin remains the first-line treatment of type 2 diabetes according to national and international guidelines. Numerous obser¬vational studies have suggested that metformin may exert beneficial therapeutic effects on diabetes - and nondiabetes - related comorbidi¬ties, including cardiovascular, hepatic, neoplastic, and infectious dis¬eases. However, direct evidence of the pleiotropic effects of metformin from specific randomized controlled trials is still lacking.